NCT02792790

Brief Summary

The investigators will prospectively evaluate tissue samples obtained from patients undergoing carpal tunnel release surgery for amyloid in the soft tissue that is removed. Patients who have tissue that stains positive for amyloid will undergo cardiac testing to look for evidence of cardiac involvement.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 20, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 8, 2016

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 21, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 2, 2021

Completed
Last Updated

December 22, 2021

Status Verified

December 1, 2021

Enrollment Period

5.4 years

First QC Date

April 20, 2016

Last Update Submit

December 21, 2021

Conditions

Keywords

AmyloidosisCarpal tunnel syndrome

Outcome Measures

Primary Outcomes (2)

  • Incidence of transthyretin (TTR) amyloidosis in patients undergoing carpal tunnel release surgery

    Identify the incidence of TTR amyloid deposits in the soft tissue of patients undergoing carpal tunnel surgery for idiopathic carpal tunnel syndrome

    Biopsy completed on day of surgery

  • Cardiac progression of transthyretin (TTR) amyloidosis in carpal tunnel biopsy-positive patients

    Assess the progression of cardiac disease in patients with TTR deposits found in soft tissue removed at the time of carpal tunnel surgery

    4 years from baseline cardiac assessment.

Secondary Outcomes (2)

  • Prevalence of abnormal transthyretin (TTR) kinetics in patients undergoing carpal tunnel surgery

    One-time kinetics test for biopsy-negative patients; baseline kinetics and annually for 4 years in biopsy-positive patients

  • Early transthyretin (TTR) amyloid cardiomyopathy identification in carpal tunnel biopsy-positive patients

    Baseline and annual testing for 4 years in biopsy-positive patients

Study Arms (1)

Patients with carpal tunnel syndrome.

Patients undergoing carpal tunnel release surgery.

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients undergoing carpal tunnel release surgery for idiopathic carpal tunnel syndrome not responding conservative and medical management.

You may qualify if:

  • Males ≥ 50 years of age
  • Females ≥ 60 years of age
  • Undergoing carpal tunnel release surgery (adequate symptoms are not responding to conservative management requiring surgery)
  • Able to consent
  • Underwent carpal tunnel surgery and biopsy within last 30 days, if the study was discussed prior to surgery by one of the study physicians.

You may not qualify if:

  • Secondary CTS (Hemodialysis, rheumatoid arthritis, trauma)
  • Known diagnosis of amyloidosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lutheran Hospital

Cleveland, Ohio, 44113, United States

Location

Related Publications (1)

  • Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050. doi: 10.1016/j.jacc.2018.07.092.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood will be stored in Cleveland Clinic to be used for the future studies.

MeSH Terms

Conditions

AmyloidosisCardiomyopathiesAmyloidosis, Hereditary, Transthyretin-RelatedCarpal Tunnel Syndrome

Condition Hierarchy (Ancestors)

Proteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic DiseasesHeart DiseasesCardiovascular DiseasesMedian NeuropathyMononeuropathiesPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesNerve Compression SyndromesCumulative Trauma DisordersSprains and StrainsWounds and Injuries

Study Officials

  • Mazen Hanna, MD

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prinicipal Investigator

Study Record Dates

First Submitted

April 20, 2016

First Posted

June 8, 2016

Study Start

March 1, 2016

Primary Completion

July 21, 2021

Study Completion

December 2, 2021

Last Updated

December 22, 2021

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share

Locations